Products
Comprehensive catalog of pharmaceutical solutions. Browse categories and send inquiries directly.
All Products (882)
| Molecule | Drug Class / Mechanism | Oncology Type | Inquiry | |
|---|---|---|---|---|
Trastuzumab |
Anti-HER2 Agent | Solid Tumour (Breast/Gastric) | ||
|
Molecule
Trastuzumab
Therapeutic Category
Targeted Therapy (Antibody / ADC)
Oncology Type
Solid Tumour (Breast/Gastric)
Drug Class / Mechanism
Anti-HER2 Agent |
||||
Trastuzumab Duocarmazine |
Anti-HER2 Agent | Solid Tumour (Breast/Gastric) | ||
|
Molecule
Trastuzumab Duocarmazine
Therapeutic Category
Targeted Therapy (Antibody / ADC)
Oncology Type
Solid Tumour (Breast/Gastric)
Drug Class / Mechanism
Anti-HER2 Agent |
||||
Triciribine |
AKT Inhibitor | Solid Tumour | ||
|
Molecule
Triciribine
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
AKT Inhibitor |
||||
Trilaciclib |
CDK Inhibitor | Solid Tumour | ||
|
Molecule
Trilaciclib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
CDK Inhibitor |
||||
Tucatinib |
EGFR / HER2 Tyrosine Kinase Inhibitor | Solid Tumour | ||
|
Molecule
Tucatinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
EGFR / HER2 Tyrosine Kinase Inhibitor |
||||
Tucidinostat |
HDAC Inhibitor | Hematologic (Lymphoma) | ||
|
Molecule
Tucidinostat
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Lymphoma)
Drug Class / Mechanism
HDAC Inhibitor |
||||
Tuvusertib |
DNA Damage Response Inhibitor (WEE1/ATR/CHK1) | Solid Tumour | ||
|
Molecule
Tuvusertib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
DNA Damage Response Inhibitor (WEE1/ATR/CHK1) |
||||
Ublituximab |
Anti-CD20 mAb | Hematologic (Lymphoma/CLL) | ||
|
Molecule
Ublituximab
Therapeutic Category
Immunotherapy (Monoclonal Antibody)
Oncology Type
Hematologic (Lymphoma/CLL)
Drug Class / Mechanism
Anti-CD20 mAb |
||||
Ulixertinib |
BRAF / MEK Inhibitor | Solid Tumour | ||
|
Molecule
Ulixertinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
BRAF / MEK Inhibitor |
||||
Umbralisib |
PI3K Inhibitor | Both (Solid & Hematologic) | ||
|
Molecule
Umbralisib
Therapeutic Category
Targeted Therapy
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
PI3K Inhibitor |
||||
Uprosertib |
AKT Inhibitor | Solid Tumour | ||
|
Molecule
Uprosertib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
AKT Inhibitor |
||||
Valemetostat |
EZH2 / Menin Inhibitor | Hematologic | ||
|
Molecule
Valemetostat
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic
Drug Class / Mechanism
EZH2 / Menin Inhibitor |
||||
TrastuzumabTargeted Therapy (Antibody / ADC) |
|
|
Therapeutic Category
Targeted Therapy (Antibody / ADC)
Oncology Type
Solid Tumour (Breast/Gastric)
Drug Class / Mechanism
Anti-HER2 Agent |
|
Trastuzumab DuocarmazineTargeted Therapy (Antibody / ADC) |
|
|
Therapeutic Category
Targeted Therapy (Antibody / ADC)
Oncology Type
Solid Tumour (Breast/Gastric)
Drug Class / Mechanism
Anti-HER2 Agent |
|
TriciribineTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
AKT Inhibitor |
|
TrilaciclibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
CDK Inhibitor |
|
TucatinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
EGFR / HER2 Tyrosine Kinase Inhibitor |
|
TucidinostatTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Lymphoma)
Drug Class / Mechanism
HDAC Inhibitor |
|
TuvusertibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
DNA Damage Response Inhibitor (WEE1/ATR/CHK1) |
|
UblituximabImmunotherapy (Monoclonal Antibody) |
|
|
Therapeutic Category
Immunotherapy (Monoclonal Antibody)
Oncology Type
Hematologic (Lymphoma/CLL)
Drug Class / Mechanism
Anti-CD20 mAb |
|
UlixertinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
BRAF / MEK Inhibitor |
|
UmbralisibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
PI3K Inhibitor |
|
UprosertibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
AKT Inhibitor |
|
ValemetostatTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic
Drug Class / Mechanism
EZH2 / Menin Inhibitor |
|